Compare Gilead Sciences, Inc. (GILD) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares TIPS Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $134.47 (market cap $163.51B), while iShares TIPS Bond ETF trades at $107.98. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares TIPS Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | TIP | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $112.20 |
52-Week Low | $108.22 | $107.91 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TIP is currently trading at $107.95, showing minimal daily movement with a slight decline of 0.06%. Technical indicators present a bearish picture, with moving averages signaling strong selling pressure, though oscillators like the RSI suggest potential oversold conditions. The company has announced upcoming dividend payments totaling $2.34 for 2026, providing income for shareholders. Financial ratios remain undisclosed in the current data snapshot, requiring further fundamental analysis.
The outlook for TIP appears cautious amid broader bond market volatility and uncertainty around Federal Reserve policy. Investment opportunities center on the attractive dividend yield, while risks include interest rate sensitivity and potential valuation pressure if bond yields continue rising. Market sentiment reflects heightened focus on fixed income dynamics as investors navigate inflationary pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
